GridAI Technologies Corp. (GRDX): Nasdaq/NYSE listing notice — First Wave BioPharma gets Nasdaq notice for bid price below $1 for 30 days

GridAI Technologies Corp.

Nasdaq notified First Wave BioPharma on Aug. 24, 2023 of non-compliance with Listing Rule 5550(a)(2).
Company has 180 days, until Feb. 20, 2024, to regain compliance by closing at $1.00 for 10+ consecutive days.
No immediate effect on listing; company may qualify for a second 180-day period if it meets other listing standards.
Failure to cure could lead to delisting, subject to appeal to a Nasdaq hearings panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

August 24, 2023, First Wave BioPharma, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effect on the

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-23-095325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.